Highlights Cessatech A/S

Equities

CESSA

DK0061411964

End-of-day quote NORDIC GROWTH MARKET Other stock markets 23:00:00 14/05/2024 BST			5-day change	1st Jan Change
5.94 ^DKK	-4.50%		-1.33%	-18.18%

02-29	Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children	25/10/23	CI
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001	21/09/23	CI
Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation	12/09/23	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
Cessatech A/S and Ventis Pharma Announce US Partnership for CT001	27/06/23	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	29/04/23	CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	01/03/23	CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2022	28/02/23	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	18/11/22	CI
Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate	23/09/22	CI
Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate	05/09/22	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	19/08/22	CI
Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval	30/06/22	CI
Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate	16/05/22	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	19/04/22	CI
Cessatech Reports Successful Outcome of Bioavailability Trial 0204 with CT001	08/03/22	CI
Cessatech A/S publishes annual report for the fiscal year 2021	03/03/22	AQ
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	24/02/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cessatech A/S

Equities

CESSA

DK0061411964

Highlights

Filters